Cytotoxic activity of zinc oxide/titanium dioxide nanoparticles on prostate cancer cells

Yıl 2019, Cilt: 3 Sayı: 2, 113 - 120, 31.12.2019

Ayca Tas , Nese Keklikcioglu Cakmak , Tugba Agbektas Yavuz Silig

https://doi.org/10.32571/ijct.613536

Cited By: 7

Öz

Prostate cancer is caused by uncontrolled growth of cells in the
prostate gland. The aim of this study was to determine the cytotoxic activity
of titanium dioxide (TiO₂) and zinc oxide (ZnO) nanoparticles (NPs)
and TiO₂ + ZnO nanocomposite (NC) in human prostate cancer cell line
(DU-145) and healthy mouse fibroblast cell line (L-929). In the study, TiO₂
and ZnO NPs and TiO₂ + ZnO NC were synthesized. Cytotoxic activities
of NC and NPs was then analyzed in human prostate cancer cell line (DU-145) and
healthy mouse fibroblast cell lines (L-929) using the MTT method. TiO₂,
ZnO and TiO₂ + ZnO IC₅₀ values were determined in DU-145
and L-929 cell cells (n = 6). TiO2 + ZnO NC in the Du-145 cell line was found
as the most active, having statistically significant (***p < 0.0001, **p ˂
0.001 and **p ˂ 0.01).

Anahtar Kelimeler

Prostate cancer, Du-145, L-929, TiO2/ZnO

Kaynakça

• 1. Hui-Ping, L.; Ching-Yu, L.; Chun-Chieh, L.; Liang-Cheng, Su Chieh, H.; Ying-Yu, K.; Jen-Chih, T.; Jong-Ming, H.; Chi-Kuan, C.; Chih-Pin, C. Int. J. Mol. Sci. 2013, 14, 5264-5283.
• 2. Szliszka, E.; Krol, W. Oncol. Rep. 2011, 26, 533-541.
• 3. Cimino, S.; Sortino, G.; Favilla, V.; Castelli, T.; Madonia, M.; Sansalone, S.; Russo, GI.; Morgia, G. Oxid Med Cell Longev. 2012, ID 632959, 8 pages.
• 4. Skandalis, S. S.; Gialeli, C.; Theocharis, A. D.; Karamanos, N. K. Adv. Cancer Res. 2014, 123, 277-317.
• 5. Jabir, N. R.; Tabrez, S.; Ashraf, G. M.; Shakil, S.; Damanhouri, G. A.; Kamal, M. A. Int. J. Nanomedicine 2012, 7, 4391-4408.
• 6. J. Wu, Y.; Wang, X.; Yang, Y.; Liu, J.; Yang, R. Nanotechnology 2012, 10, 23-35.
• 7. Yang, D.; Wenzhi, R.; Yaqian, L.; Qian, Z.; Leyong, Z.; Chongwei, C.; Aiguo, W.; Jie, T. Royal Soc. Chem. 2015, 16, 38-59.
• 8. Rozhkova, EA.; Ulasov, I.; Lai, B.; Dimitrijevic, NM.; Lesniak, MS.; Rajh, T. Nano Lett. 2009, 9, 3337-3342.
• 9. S. Shen, X.; Guo, L.; Wu, M.; Wang, X.; Wang, F.; Kong, H.; Shen, M.; Xie, Y. J. Mater. Chem. 2014, 2, 5775-5784.
• 10. Zhao, C.; Zhang, X.; Zheng, Y. J. Photochem. Photobiol. B: Biology 2018, 183, 142-146.
• 11. Carp, O.; Huisman, C. L.; Reller, A. Prog. Solid State Chem. 2004, 32, 33-177.
• 12. Zhou, J.; Xu, N. S.; Wang, Z. L. Adv. Mater. 2006, 18 (18), 2432-2435.
• 13. Tas, A.; Cakmak, N. K.; Silig, Y. Inter. J. Modern Res. Eng. Technol. 2018, 3.
• 14. Rrajendar, V.; Raghu, Y.; Rajitha, B.; Chakra, C. S.; Rao, K. V.; Park, S. H. J. Ovonic Res. 2017, 13.
• 15. Bolukbasi Sahin, S.; Keklikcioglu Cakmak, N.; Tas, A.; Ozmen, E.; Cevik, E.; Gumus, E.; Silig, Y. Int. J. Sci. Technol. Res. 2018, 4 (8), 78-84.
• 16. Skehan, P.; Storeng, R.; Scudiero, D.; Monks, A.; McMahon, J.; Vistica, D.; Warren, J. T.; Bokesch, H.; Kenney, S.; Boyd, M. R. J. Natl. Cancer Inst. 1990, 82, 1107-1112.
• 17. Von der Kammer, F, Ottofuelling, S.; Hofmann, T. Environ. Pollut. 2010, 158, 3472-3481.
• 18. McNeil, S. E. J. Leukoc. Biol. 2005, 78, 585-594.
• 19. Bisht, G.; Rayamajhi, S. Nanobiomedicine 2016, 3, 3-9.
• 20. Cho, W. S; Kang, B. C; Lee, J. K.; Jeong, J.; Che, J. H; Seok, S. H. Part Fibre Toxicol. 2013, 10, 9.
• 21. Hanley, C.; Layne, J.; Punnoose, A.; Reddy, K. M.; Coombs, I.; Coombs, I.; Coombs, A.; Feris, K.; Wingett, D. Nanotechnology 2008, 19 (29), 295103.
• 22. Kansara, K.; Patel, P.; Shah, D.; Shukla, R. K.; Singh, S.; Kumar, A.; Dhawan, A. Environ. Mol. Mutagen. 2015, 56 (2), 204-217.
• 23. Tomasina, J.; Poulain, L.; Abeilard, E.; Giffard, F.; Brotin, E.; Carduner, L. Malzert-Fréon, A. Int. J. Pharm. 2013, 458 (1), 197-207.
• 24. Fadoju, O.; Ogunsuyi, O.; Akanni, O.; Alabi, O.; Alimba, C.; Adaramoye, O. Bakare, A. Environ. Toxicol. Pharm. 2019, 103204.